Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease

-- Long-Acting Muscarinic Antagonist (LAMA) Bronchodilator in
Pearl's Proprietary High-Performance Metered Dose Inhaler (MDI)
Product Shown To Be Comparable to Spiriva(R) in Patients with COPD
--
REDWOOD CITY, Calif., Jan. 6 /PRNewswire/ -- Pearl...